Domestic returns from investment in the control of tuberculosis in other countries

New England Journal of Medicine

Volumn 353, Issue 10, 2005, Pages 1008-1020

  Schwartzman, Kevin ^a   Oxlade, Olivia ^a   Graham Barr, R ^c   Grimard, Franque ^b   Acosta, Ivelisse ^d   Baez, Jeannette ^e   Ferreira, Elizabeth ^f   Melgen, Ricardo Elías ^d   Morose, Willy ^g   Salgado, Arturo Cruz ^f   Jacquet, Vary ^g   Maloney, Susan ^h   Laserson, Kayla ^h   Mendez, Ariel Pablos ⁱ   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c NewYork Presbyterian Hospital   (United States)

^d National Tuberculosis Control Program   (Dominican Republic)

^e Centro Nacional de Investigaciones en Salud Materno Infantil   (Dominican Republic)

^f National Tuberculosis Action Program   (Mexico)

^g National Tuberculosis Control Programme   (Haïti)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOMINICAN REPUBLIC; FINANCIAL MANAGEMENT; HAITI; HEALTH PROGRAM; HUMAN; IMMIGRANT; INCIDENCE; INVESTMENT; LEGAL ASPECT; MEXICO; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RADIOGRAPHY; REFUGEE; SCREENING TEST; STATISTICAL MODEL; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES;

ANTITUBERCULAR AGENTS; COST SAVINGS; DECISION SUPPORT TECHNIQUES; DIRECTLY OBSERVED THERAPY; DOMINICAN REPUBLIC; EMIGRATION AND IMMIGRATION; HAITI; HEALTH CARE COSTS; HUMANS; INCIDENCE; INTERNATIONAL COOPERATION; INVESTMENTS; LUNG; MARKOV CHAINS; MASS SCREENING; MEXICO; MODELS, ECONOMIC; RADIOGRAPHY, THORACIC; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; UNITED STATES;

EID: 24344450247     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsa043194     Document Type: Article

References (63)

1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-21.
2. Reported tuberculosis in the United States, 2002. Atlanta: Centers for Disease Control and Prevention, 2003. (Accessed August 22, 2005, at http://www.cdc.gov/nchstp/ tb/surv/surv2002/default.htm.)
3. Ellis E, Sauvé L, Phypers M, Sheardown C, Allegakone M. Tuberculosis statistics 2003. Ottawa: Public Health Agency of Canada, 2004. (Accessed August 11, 2005, at http:// www.phac-aspc.gc.ca/publicat/tbcan02/ index.html.)
4. Reported tuberculosis in the United States, 2001 - tuberculosis case rates: United States, 2001. Atlanta: Centers for Disease Control and Prevention, 2001. (Accessed August 11, 2005, at http://www.cdc.gov/ nchstp/tb/surv/ surv2001/default.htm.)
5. Binkin NJ, Zuber PLF, Wells CD, Tipple MA, Castro KG. Overseas screening for tuberculosis in immigrants and refugees to the United States: current status. Clin Infect Dis 1996;23:1226-32.
6. Coker RJ, Bell A, Pitman R, Hayward A, Watson J. Screening programmes for tuberculosis in new entrants across Europe. Int J Tuberc Lung Dis 2004;8:1022-6.
7. Geiter L, ed. Ending neglect: the elimination of tuberculosis in the United States. Washington, D.C.: National Academies Press, 2000.
8. Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347:1850-9.
9. Dasgupta K, Schwartzman K, Marchand R, Tennenbaum TN, Brassard P, Menzies D. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000;162:2079-86.
10. Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003;7(Suppl 3):S384-S390.
11. British Columbia Center for Disease Control. Annual report: tuberculosis control in 2002. Vancouver, Canada: British Columbia Ministry of Health, 2003.
12. Office of Immigration Statistics. 2002 Yearbook of immigration statistics - October 2003. Washington, D.C.: Department of Homeland Security, 2003.
13. ITA Office of Travel and Tourism Industries. Information on inbound travel to the US. (Accessed August 11, 2005, at http:// tinet.ita.doc.gov/ outreachpages/index. html#inbound.)
14. McCarthy OR. Asian immigrant tuberculosis - the effect of visiting Asia. Br J Dis Chest 1984;78:248-53.
15. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. Geneva: World Health Organization, 1997.
16. Suarez PG, Watt CJ, Alarcon E, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis 2001;184:473-8.
17. Elzinga G, Raviglione MC, Maher D. Scale up: meeting targets in global tuberculosis control. Lancet 2004;363:814-9.
18. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet 2004;364:417-22.
19. Floyd K, Blanc L, Raviglione M, Lee JW. Resources required for global tuberculosis control. Science 2002;295:2040-1.
20. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford, England: Oxford University Press, 1987.
21. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1253-8.
22. Zuber PLF, Binkin NJ, Ignacio AC, et al. Tuberculosis screening for immigrants and refugees: diagnostic outcomes in the State of Hawaii. Am J Respir Crit Care Med 1996; 154:151-5.
23. Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees: a five-year surveillance study. Am Rev Respir Dis 1988;137:805-9.
24. Styblo K. The relationship between the risk of tuberculosis infection and the risk of developing infectious tuberculosis. Bull Int Union Tuberc 1985;60:117-9.
25. Further studies of geographic variation in naturally acquired tuberculin sensitivity. Bull World Health Organ 1955;12:63-83.
26. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries: a cost-effectiveness analysis. Am J Respir Crit Care Med 2000;161:780-9.
27. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-50.
28. Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis 1986;133:431-6.
29. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155:1595-600.
30. UNAIDS home page. Joint United Nations Programme on HIV/AIDS. (Accessed August 11, 2005, at http://www.unaids.org/ EN/default.asp#.)
31. Granich RM, Balandrano S, Santaella AJ, et al. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997. Arch Intern Med 2000;160:639-44.
32. World Bank home page: data by country. (Accessed August 11, 2005, at http:// www.worldbank.org/data/countrydata/ countrydata.html.)
33. Lubotsky D. The effect of changes in the U.S. wage structure on recent immigrants' earnings. Princeton, N.J.: Research Program in Development Studies, Woodrow Wilson School of Public and International Affairs, 2001.
34. Green DA, Worswick C. Immigrant earnings profiles in the presence of human capital investment: measuring cohort and macro effects. Vancouver, Canada: University of British Columbia, 2003.
35. Borjas G. The economic analysis of immigration. In: Ashenfelter OC, ed. Handbook of labor economics. New York: Elsevier, 1999:1697-760.
36. Groth-Peterson E, Knudsen J, Wilbek E. Epidemiological basis of tuberculosis eradication in an advanced country. Bull World Health Organ 1959;21:5-49.
37. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970;26:28-106.
38. Blum RN, Polish LB, Tapy JM, Catlin BJ, Cohn DL. Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status. Chest 1993;103:1670-4.
39. Catlos EK, Cantwell MF, Bhatia G, Gedin S, Lewis J, Mohle-Boetani JC. Public health interventions to encourage TB class A/B1/B2 immigrants to present for TB screening. Am J Respir Crit Care Med 1998; 158:1037-41.
40. Moran-Mendoza AO. The value of the tuberculin skin test size in predicting the development of tuberculosis in contacts of active cases. Vancouver, Canada: University of British Columbia, 2004.
41. Yuan L, Richardson E, Kendall PRW. Evaluation of a tuberculosis screening program for high-risk students in Toronto schools. CMAJ 1995;153:925-32.
42. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001.
43. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8.
44. Reported tuberculosis in the United States, 2000. Atlanta: Centers for Disease Control and Prevention, 2000. (Accessed August 11, 2005, at http://www.cdc.gov/ nchstp/tb/surv/surv2000/default.htm.)
45. Lee JW, Espinal M, Jaramillo E. Report of site visit to evaluate DOTS expansion in Latin America. Geneva: World Health Organization, 2002.
46. Vaca J, Peralta H, Gresely L, et al. DOTS implementation in a middle-income country: development and evaluation of a novel approach. Int J Tuberc Lung Dis 2005;9: 521-7.
47. Global Drug Facility. First-line tuberculosis drugs and formulations currently supplied/ to be supplied by the global TB drug facility. Geneva: World Health Organization. (Accessed August 11, 2005, at http:// www.stoptb.org/gdf/ drugsupply/drugs_ available.asp.)
48. Global tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization, 2003. (Accessed August 11, 2005, at http://www.who.int/ docstore/gtb/publications/globrep03/.)
49. Sutherland I. The evolution of clinical tuberculosis in adolescents. Tubercle 1966; 47:308.
50. Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974;110:572-80.
51. Rieder HL. Epidemiologic basis of tuberculosis control. Paris: International Union Against Tuberculosis and Lung Disease, 1999.
52. Grzybowski S, Enarson DA. Results in pulmonary tuberculosis patients under various treatment conditions. Bull Int Union Tuberc 1978;53:70-5. (In French.)
53. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-8.
54. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000;23:75-80.
55. Murray J, Sonnenberg P, Shearer SC, Godgrey-Faussett P. Human immunodeficiency virus and outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999;159:733-40.
56. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687-93. [Erratum, Lancet 2002; 359:2120.]
57. Consumer price index. Washington, D.C.: Department of Labor, Bureau of Labor Statistics. (Accessed August 11, 2005, at http:// www.stats.bls.gov.)
58. Global tuberculosis control: surveillance, planning, financing. Annex 4. Regional profile for the Americas: notification, detection and DOTS coverage, 2001. Geneva: World Health Organization, 2003. (Accessed August 11, 2005, at http://www.who.int/docstore/gtb/publications/globrep03/pdf/rep_sections/ 4_page_143-180.pdf.)
59. Pitchenik AE, Russell BW, Cleary T, Pejovic I, Cole C. Snider DE Jr. The prevalence of tuberculosis and drug resistance among Haitians. N Engl J Med 1982;307:162-5.
60. Espinal MA, Baez J, Soriano G, et al. Drug-resistant tuberculosis in the Dominican Republic: results of a nationwide survey. Int J Tuberc Lung Dis 1998;2:490-8.
61. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990;65:6-24.
62. Dye C, Fengzeng Z, Scheele S, Williams B. Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol 2000;29:558-64.
63. Khatri GR, Frieden TR. Controlling tuberculosis in India. N Engl J Med 2002;347: 1420-5.